What the test looks for
Detection of a ROS1 gene rearrangement, present in 1 to 2% of non-small cell lung cancers, often in non-smokers.
Screening by immunohistochemistry and confirmation by FISH. A ROS1 rearrangement makes the patient eligible for ROS1 inhibitors.
Required sample
- FFPE tumour block.
- At least 50 assessable tumour cells for FISH.
- Pathology report enclosed.